Hyoscine
- scopolamine
- Hyoscine
- 51-34-3
- (-)-Hyoscine
- Scopine (-)-tropate
- Create:2005-06-29
- Modify:2025-01-18
- Boro Scopol
- Boro-Scopol
- Hyoscine
- Isopto Hyoscine
- Kwells
- Scoburen
- Scopace
- Scopoderm TTS
- Scopolamine
- Scopolamine Cooper
- Scopolamine Hydrobromide
- Transderm Scop
- Transderm V
- Transderm-V
- Travacalm HO
- Vorigeno
- scopolamine
- Hyoscine
- 51-34-3
- (-)-Hyoscine
- Scopine (-)-tropate
- Scopine tropate
- (-)-Scopolamine
- Hyosol
- 6,7-Epoxytropine tropate
- Transderm-Scop
- Atrochin
- Atroquin
- Isopto Hyoscine
- Skopolamin
- l-Scopolamine
- Epoxytropine tropate
- Scopolamine hydrobromide
- 6-beta,7-beta-Epoxy-3-alpha-tropanyl S-(-)-tropate
- Beldavrin
- Scopamin
- Kwells
- alpha-(Hydroxymethyl)benzeneacetic acid 9-methyl-3-oxa-9-azatricyclo(3.3.1.0(2.4))non-7-yl ester
- Hyosceine
- Transcop
- Scop
- DL48G20X8X
- Tropic acid, ester with scopine
- CHEMBL3084722
- CHEBI:16794
- Euscopol
- Isoscopil
- Tranaxine
- (1S,3S,5R,6R,7S)-6,7-epoxytropan-3-yl (2S)-3-hydroxy-2-phenylpropanoate
- Hysco
- Hyoscine bromide
- Scopace
- Transderm scop
- Scopolamine HCl
- Boro-Scopol
- Hyoscine hydrobromide
- Scopolaminium bromide
- 1alphaH,5alphaH-Tropan-3alpha-ol, 6beta,7beta-epoxy-, (-)-tropate (ester)
- Scopolammonium bromide
- l-Hyoscine hydrobromide
- SEE
- (-)-Scopolamine bromide
- l-Scopolamine-hydrobromide
- SCOPOLAMINE BROMIDE
- (-)-Hyoscine hydrobromide
- Scopoderm
- levo-duboisine
- (+)-Hyoscine
- (1R,2R,4S,5S,7S)-9-methyl-3-oxa-9-azatricyclo[3.3.1.0(2,4)]non-7-yl (2S)-3-hydroxy-2-phenylpropanoate
- (1R,2R,4S,5S,7s)-9-Methyl-3-oxa-9-azatricyclo[3.3.1.0~2,4~]nonan-7-yl (2S)-3-hydroxy-2-phenylpropanoate
- Hyoscyine hydrobromide
- Hydroscine hydrobromide
- hydrobromicum, Scopolaminum
- UNII-DL48G20X8X
- Tropane alkaloid
- HSDB 4074
- 6.beta.,7.beta.-Epoxy-1.alpha.H,5.alpha.H-tropan-3.alpha.-ol (-)-tropate (ester)
- EINECS 200-090-3
- NSC61806
- S-(-)-Tropate
- SCOPOLAMINE [MI]
- Prestwick3_000877
- HYOSCINE [MART.]
- SCOPOLAMINE [HSDB]
- HYOSCINE [WHO-DD]
- EC 200-090-3
- SCOPOLAMINE [VANDF]
- (-)-Scopolamin (Hyoscine)
- 6beta,7beta-Epoxy-3alpha-tropanyl S-(-)-tropate
- SCHEMBL16226
- BSPBio_000953
- GTPL330
- 6beta,7beta-Epoxy-1alpha,5alpha-tropan-3alpha-ol
- HYOSCINE [EP IMPURITY]
- BPBio1_001049
- CHEMBL569713
- HYOSCINE [EP MONOGRAPH]
- CHEMBL1906925
- DTXSID6023573
- SCHEMBL22393238
- CHEBI:93572
- SCOPOLAMINE [ORANGE BOOK]
- STECJAGHUSJQJN-FWXGHANASA-N
- HMS2090N13
- HMS3886L22
- SCOPOLAMINE [USP IMPURITY]
- (1R,2R,4S,5S,7s)-9-methyl-3-oxa-9-azatricyclo[3.3.1.02,4]nonan-7-yl (S)-3-hydroxy-2-phenylpropanoate
- HY-N0296
- LSM-4015
- AC-968
- BDBM50263508
- s9326
- AKOS025402477
- Scopolamine dried down 100 microg/mL
- Tropic acid, 9-methyl-3-oxa-9-azatricyclo(3.3.1.0(sup 2,4))non-7-yl ester
- CCG-267504
- CS-6609
- DB00747
- 3-Oxa-9-azatricyclo(3.3.1.0(sup 2,4))nonan-7-ol, 9-methyl-, tropate (ester)
- 3-Oxa-9-azatricyclo(3.3.1.O(sup 2,4))nonan-7-ol, 9-methyl-, tropate (ester)
- SMP1_000270
- NCGC00024357-04
- NCGC00024357-05
- 1ST10286
- DA-67494
- Scopolamine 100 microg/mL in Acetonitrile
- AB00429689
- AB00429689-30
- AB00429689-31
- AB00429689_32
- EN300-1718536
- ATROPINE SULFATE IMPURITY F [EP IMPURITY]
- Q337188
- (methyl[?]yl) (2S)-3-hydroxy-2-phenyl-propanoate
- BRD-K89923877-003-02-4
- BRD-K89923877-004-15-4
- BRD-K89923877-004-16-2
- Q27165268
- (1R,2R,4S,5S,7R)-9-methyl-3-oxa-9-azatricyclo[3.3.1.0,2,4]nonan-7-yl (2S)-3-hydroxy-2-phenylpropanoate
- (1R,2R,4S,5S,7R)-9-methyl-3-oxa-9-azatricyclo[3.3.1.0,nonan-7-yl (2S)-3-hydroxy-2-phenylpropanoate
- (1R,2R,4S,5S,7S)-9-METHYL-3-OXA-9-AZATRICYCLO(3.3.1.02,4)NON-7-YL (2S)-3-HYDROXY-2-PHENYLPROPANOATE
- (1R,2R,4S,5S,7S)-9-methyl-3-oxa-9-azatricyclo[3.3.1.0^{2,4}]nonan-7-yl (2S)-3-hydroxy-2-phenylpropanoate
- (1R,2R,4S,5S,7S)-9-methyl-3-oxa-9-azatricyclo[3.3.1.0~2,4~]non-7-yl (2S)-3-hydroxy-2-phenylpropanoate
- (1R,2R,4S,5S,7S)-9-methyl-3-oxa-9-azatricyclo[3.3.1.02,4]non-7-yl (2R)-3-hydroxy-2-phenylpropanoate
- (1R,2R,4S,5S,7s)-9-methyl-3-oxa-9-azatricyclo[3.3.1.02,4]nonan-7-yl (2S)-3-hydroxy-2-phenylpropanoate
- [(1R,2R,4S,5S)-9-methyl-3-oxa-9-azatricyclo[3.3.1.02,4]nonan-7-yl] (2S)-3-hydroxy-2-phenylpropanoate
- [7(S)-(1.alpha.,2.beta.,4.beta.,5.alpha.,7.beta.)]-.alpha.-(Hydroxymethyl)benzeneacetic acid 9-methyl-3-oxa-9-azatricyclo-[3.3.1.0^2,4]non-7-yl ester
- BENZENEACETIC ACID, .ALPHA.(HYDROXYMETHYL)-,(1.ALPHA.,2.BETA.,4.BETA.,5.ALPHA.,7.BETA.)-9-METHYL-3-OXA-9-AZATRICYCLO(3.3.1.02,4)NON-7-YL ESTER, (.ALPHA.S)-
- BENZENEACETIC ACID, .ALPHA.-(HYDROXYMETHYL)-, 9-METHYL-3-OXA-9-AZATRICYCLO(3.3.1.02,4)NON-7-YL ESTER, (7(S)-(1.ALPHA.,2.BETA.,4.BETA.,5.ALPHA.,7.BETA.))-
- Benzeneacetic acid, alpha-(hydroxymethyl)-, (1alpha,2beta,4beta,5alpha,7beta)-9-methyl-3-oxa-9-azatricyclo(3.3.1.02,4)non-7-yl ester, (alphaS)-
- Benzeneacetic acid, alpha-(hydroxymethyl)-, 9-methyl-3-oxa-9-azatricyclo(3.3.1.02,4)non-7-yl ester, (7(S)-(1alpha,2beta,4beta,5alpha,7beta))-
- OW0
94.0 1
138.0 0.76
108.0 0.34
154.0 0.27
97.0 0.24
304.15434 999
326.136282 59
138.091118 0.55
156.101791 0.22
121.064451 0.13
110.094002 0.05
98.059409 0.03
S - Sensory organs
S01 - Ophthalmologicals
S01F - Mydriatics and cycloplegics
S01FA - Anticholinergics
S01FA02 - Scopolamine
H300 (100%): Fatal if swallowed [Danger Acute toxicity, oral]
H310 (100%): Fatal in contact with skin [Danger Acute toxicity, dermal]
H330 (100%): Fatal if inhaled [Danger Acute toxicity, inhalation]
P260, P262, P264, P270, P271, P280, P284, P301+P316, P302+P352, P304+P340, P316, P320, P321, P330, P361+P364, P403+P233, P405, and P501
(The corresponding statement to each P-code can be found at the GHS Classification page.)
Aggregated GHS information provided per 14 reports by companies from 2 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown.
Acute Tox. 2 (100%)
Acute Tox. 1 (100%)
Acute Tox. 2 (100%)
Acute Tox. 2 (33.3%)
Acute Tox. 4 (66.7%)
Acute Tox. 1 (33.3%)
Acute Tox. 2 (33.3%)
Repr. 2 (33.3%)
SYMPTOMS: Symptoms of exposure to this chemical include drowsiness, sleepiness, excitement, hallucinations, delirium, psychotic behavior and central nervous system depression. Other symptoms include narcosis, mydriasis, dryness of the mouth and restlessness. It can also cause temporary loss of accommodation and tachycardia. Dulling of mental alertness may occur. It may also cause irritation.
ACUTE/CHRONIC HAZARDS: This compound may be harmful by ingestion or inhalation. It may cause irritation. When heated to decomposition it emits toxic fumes of carbon monoxide, carbon dioxide, nitrogen oxides and hydrogen bromide gas. (NTP, 1992)
EYES: First check the victim for contact lenses and remove if present. Flush victim's eyes with water or normal saline solution for 20 to 30 minutes while simultaneously calling a hospital or poison control center. Do not put any ointments, oils, or medication in the victim's eyes without specific instructions from a physician. IMMEDIATELY transport the victim after flushing eyes to a hospital even if no symptoms (such as redness or irritation) develop.
SKIN: IMMEDIATELY flood affected skin with water while removing and isolating all contaminated clothing. Gently wash all affected skin areas thoroughly with soap and water. If symptoms such as redness or irritation develop, IMMEDIATELY call a physician and be prepared to transport the victim to a hospital for treatment.
INHALATION: IMMEDIATELY leave the contaminated area; take deep breaths of fresh air. If symptoms (such as wheezing, coughing, shortness of breath, or burning in the mouth, throat, or chest) develop, call a physician and be prepared to transport the victim to a hospital. Provide proper respiratory protection to rescuers entering an unknown atmosphere. Whenever possible, Self-Contained Breathing Apparatus (SCBA) should be used; if not available, use a level of protection greater than or equal to that advised under Protective Clothing.
INGESTION: DO NOT INDUCE VOMITING. If the victim is conscious and not convulsing, give 1 or 2 glasses of water to dilute the chemical and IMMEDIATELY call a hospital or poison control center. Be prepared to transport the victim to a hospital if advised by a physician. If the victim is convulsing or unconscious, do not give anything by mouth, ensure that the victim's airway is open and lay the victim on his/her side with the head lower than the body. DO NOT INDUCE VOMITING. IMMEDIATELY transport the victim to a hospital. (NTP, 1992)
SMALL SPILLS AND LEAKAGE: If you spill this chemical, you should dampen the solid spill material with water, then transfer the dampened material to a suitable container. Use absorbent paper dampened with water to pick up any remaining material. Seal your contaminated clothing and the absorbent paper in a vapor-tight plastic bag for eventual disposal. Wash all contaminated surfaces with a soap and water solution. Do not reenter the contaminated area until the Safety Officer (or other responsible person) has verified that the area has been properly cleaned.
STORAGE PRECAUTIONS: You should protect this chemical from exposure to light. Keep the container tightly closed under an inert atmosphere, and store under refrigerated temperatures. (NTP, 1992)
Alcohols and Polyols
Esters, Sulfate Esters, Phosphate Esters, Thiophosphate Esters, and Borate Esters
Hydrocarbons, Aromatic
Epoxides
Salts, Acidic
◉ Summary of Use during Lactation
No information is available on the use of scopolamine during breastfeeding. Use during labor appears to have a detrimental effect on newborn infants' nursing behavior. Long-term use of scopolamine might reduce milk production or milk letdown, but a single systemic or ophthalmic dose is not likely to interfere with breastfeeding. During long-term use, observe for signs of decreased lactation (e.g., insatiety, poor weight gain). To substantially diminish the amount of drug that reaches the breastmilk after using eye drops, place pressure over the tear duct by the corner of the eye for 1 minute or more, then remove the excess solution with an absorbent tissue.
◉ Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
◉ Effects on Lactation and Breastmilk
Anticholinergics can inhibit lactation in animals, apparently by inhibiting growth hormone and oxytocin secretion. Anticholinergic drugs can also reduce serum prolactin in nonnursing women. The prolactin level in a mother with established lactation may not affect her ability to breastfeed.
A retrospective case-control study conducted in two hospitals in central Iran compared breastfeeding behaviors in the first 2 hours postdelivery by infants of 4 groups of primiparous women with healthy, full-term singleton births who had vaginal deliveries. The groups were those who received no medications during labor, those who received oxytocin plus scopolamine, those who received oxytocin plus meperidine, and those who received oxytocin, scopolamine and meperidine. The infants in the no medication group performed better than those in all other groups, and the oxytocin plus scopolamine group performed better than the groups that had received meperidine.
Patents are available for this chemical structure:
https://patentscope.wipo.int/search/en/result.jsf?inchikey=STECJAGHUSJQJN-FWXGHANASA-N
- CAMEO ChemicalsLICENSECAMEO Chemicals and all other CAMEO products are available at no charge to those organizations and individuals (recipients) responsible for the safe handling of chemicals. However, some of the chemical data itself is subject to the copyright restrictions of the companies or organizations that provided the data.https://cameochemicals.noaa.gov/help/reference/terms_and_conditions.htm?d_f=falseSCOPOLAMINE HYDROBROMIDEhttps://cameochemicals.noaa.gov/chemical/21003CAMEO Chemical Reactivity Classificationhttps://cameochemicals.noaa.gov/browse/react
- ChemIDplusChemIDplus Chemical Information Classificationhttps://pubchem.ncbi.nlm.nih.gov/source/ChemIDplus
- DrugBankLICENSECreative Common's Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/legalcode)https://www.drugbank.ca/legal/terms_of_useScopolaminehttps://www.drugbank.ca/drugs/DB00747
- EPA DSSToxCompTox Chemicals Dashboard Chemical Listshttps://comptox.epa.gov/dashboard/chemical-lists/
- European Chemicals Agency (ECHA)LICENSEUse of the information, documents and data from the ECHA website is subject to the terms and conditions of this Legal Notice, and subject to other binding limitations provided for under applicable law, the information, documents and data made available on the ECHA website may be reproduced, distributed and/or used, totally or in part, for non-commercial purposes provided that ECHA is acknowledged as the source: "Source: European Chemicals Agency, http://echa.europa.eu/". Such acknowledgement must be included in each copy of the material. ECHA permits and encourages organisations and individuals to create links to the ECHA website under the following cumulative conditions: Links can only be made to webpages that provide a link to the Legal Notice page.https://echa.europa.eu/web/guest/legal-noticeHyoscine hydrobromidehttps://chem.echa.europa.eu/100.003.682Hyoscine (EC: 200-090-3)https://echa.europa.eu/information-on-chemicals/cl-inventory-database/-/discli/details/10738Hyoscine hydrobromide (EC: 204-050-6)https://echa.europa.eu/information-on-chemicals/cl-inventory-database/-/discli/details/20293
- FDA Global Substance Registration System (GSRS)LICENSEUnless otherwise noted, the contents of the FDA website (www.fda.gov), both text and graphics, are not copyrighted. They are in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from FDA. Credit to the U.S. Food and Drug Administration as the source is appreciated but not required.https://www.fda.gov/about-fda/about-website/website-policies#linking
- Hazardous Substances Data Bank (HSDB)
- New Zealand Environmental Protection Authority (EPA)LICENSEThis work is licensed under the Creative Commons Attribution-ShareAlike 4.0 International licence.https://www.epa.govt.nz/about-this-site/general-copyright-statement/
- ChEBI
- FDA Pharm ClassesLICENSEUnless otherwise noted, the contents of the FDA website (www.fda.gov), both text and graphics, are not copyrighted. They are in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from FDA. Credit to the U.S. Food and Drug Administration as the source is appreciated but not required.https://www.fda.gov/about-fda/about-website/website-policies#linkingFDA Pharmacological Classificationhttps://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/ucm162549.htm
- LOTUS - the natural products occurrence databaseLICENSEThe code for LOTUS is released under the GNU General Public License v3.0.https://lotus.nprod.net/LOTUS Treehttps://lotus.naturalproducts.net/
- NCI Thesaurus (NCIt)LICENSEUnless otherwise indicated, all text within NCI products is free of copyright and may be reused without our permission. Credit the National Cancer Institute as the source.https://www.cancer.gov/policies/copyright-reuseNCI Thesaurushttps://ncit.nci.nih.gov
- Open TargetsLICENSEDatasets generated by the Open Targets Platform are freely available for download.https://platform-docs.opentargets.org/licence
- CCSbaseCCSbase Classificationhttps://ccsbase.net/
- ChEMBLLICENSEAccess to the web interface of ChEMBL is made under the EBI's Terms of Use (http://www.ebi.ac.uk/Information/termsofuse.html). The ChEMBL data is made available on a Creative Commons Attribution-Share Alike 3.0 Unported License (http://creativecommons.org/licenses/by-sa/3.0/).http://www.ebi.ac.uk/Information/termsofuse.htmlChEMBL Protein Target Treehttps://www.ebi.ac.uk/chembl/g/#browse/targets
- Comparative Toxicogenomics Database (CTD)LICENSEIt is to be used only for research and educational purposes. Any reproduction or use for commercial purpose is prohibited without the prior express written permission of NC State University.http://ctdbase.org/about/legal.jsp
- Drug Gene Interaction database (DGIdb)LICENSEThe data used in DGIdb is all open access and where possible made available as raw data dumps in the downloads section.http://www.dgidb.org/downloadsSCOPOLAMINEhttps://www.dgidb.org/drugs/rxcui:9601JNJ-40068782https://www.dgidb.org/drugs/iuphar.ligand:6330
- IUPHAR/BPS Guide to PHARMACOLOGYLICENSEThe Guide to PHARMACOLOGY database is licensed under the Open Data Commons Open Database License (ODbL) https://opendatacommons.org/licenses/odbl/. Its contents are licensed under a Creative Commons Attribution-ShareAlike 4.0 International License (http://creativecommons.org/licenses/by-sa/4.0/)https://www.guidetopharmacology.org/about.jsp#licenseGuide to Pharmacology Target Classificationhttps://www.guidetopharmacology.org/targets.jsp
- ClinicalTrials.govLICENSEThe ClinicalTrials.gov data carry an international copyright outside the United States and its Territories or Possessions. Some ClinicalTrials.gov data may be subject to the copyright of third parties; you should consult these entities for any additional terms of use.https://clinicaltrials.gov/ct2/about-site/terms-conditions#Use
- Therapeutic Target Database (TTD)
- DailyMedSCOPOLAMINE HYDROBROMIDEhttps://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=SCOPOLAMINE+HYDROBROMIDE
- IUPAC Digitized pKa Dataset
- Drugs and Lactation Database (LactMed)
- Drugs@FDALICENSEUnless otherwise noted, the contents of the FDA website (www.fda.gov), both text and graphics, are not copyrighted. They are in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from FDA. Credit to the U.S. Food and Drug Administration as the source is appreciated but not required.https://www.fda.gov/about-fda/about-website/website-policies#linking
- WHO Model Lists of Essential MedicinesLICENSEPermission from WHO is not required for the use of WHO materials issued under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Intergovernmental Organization (CC BY-NC-SA 3.0 IGO) license.https://www.who.int/about/policies/publishing/copyrightHyoscine hydrobromidehttps://list.essentialmeds.org/medicines/281
- EU Clinical Trials Register
- Hazardous Chemical Information System (HCIS), Safe Work Australia
- Regulation (EC) No 1272/2008 of the European Parliament and of the CouncilLICENSEThe copyright for the editorial content of this source, the summaries of EU legislation and the consolidated texts, which is owned by the EU, is licensed under the Creative Commons Attribution 4.0 International licence.https://eur-lex.europa.eu/content/legal-notice/legal-notice.html
- FDA Orange BookLICENSEUnless otherwise noted, the contents of the FDA website (www.fda.gov), both text and graphics, are not copyrighted. They are in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from FDA. Credit to the U.S. Food and Drug Administration as the source is appreciated but not required.https://www.fda.gov/about-fda/about-website/website-policies#linking
- NORMAN Suspect List ExchangeLICENSEData: CC-BY 4.0; Code (hosted by ECI, LCSB): Artistic-2.0https://creativecommons.org/licenses/by/4.0/ScopolamineNORMAN Suspect List Exchange Classificationhttps://www.norman-network.com/nds/SLE/
- National Drug Code (NDC) DirectoryLICENSEUnless otherwise noted, the contents of the FDA website (www.fda.gov), both text and graphics, are not copyrighted. They are in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from FDA. Credit to the U.S. Food and Drug Administration as the source is appreciated but not required.https://www.fda.gov/about-fda/about-website/website-policies#linking
- MassBank of North America (MoNA)LICENSEThe content of the MoNA database is licensed under CC BY 4.0.https://mona.fiehnlab.ucdavis.edu/documentation/license
- Kruve Lab, Ionization & Mass Spectrometry, Stockholm Universityscopolamine
- Natural Product Activity and Species Source (NPASS)
- MassBank Europe
- Metabolomics Workbench
- Nature Chemical Biology
- NIPH Clinical Trials Search of Japan
- NLM RxNorm TerminologyLICENSEThe RxNorm Terminology is created by the National Library of Medicine (NLM) and is in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from NLM. Credit to the U.S. National Library of Medicine as the source is appreciated but not required. The full RxNorm dataset requires a free license.https://www.nlm.nih.gov/research/umls/rxnorm/docs/termsofservice.htmlscopolaminehttps://rxnav.nlm.nih.gov/id/rxnorm/9601scopolamine hydrobromidehttps://rxnav.nlm.nih.gov/id/rxnorm/9603
- WHO Anatomical Therapeutic Chemical (ATC) ClassificationLICENSEUse of all or parts of the material requires reference to the WHO Collaborating Centre for Drug Statistics Methodology. Copying and distribution for commercial purposes is not allowed. Changing or manipulating the material is not allowed.https://www.whocc.no/copyright_disclaimer/
- PharosLICENSEData accessed from Pharos and TCRD is publicly available from the primary sources listed above. Please respect their individual licenses regarding proper use and redistribution.https://pharos.nih.gov/aboutscopolaminehttps://pharos.nih.gov/ligands/W4NG2JW7F46Yscopolaminehttps://pharos.nih.gov/ligands/W4NG446XR2XVScopolaminehttps://pharos.nih.gov/ligands/W4NQGUUHZT1Y
- Protein Data Bank in Europe (PDBe)
- Rhea - Annotated Reactions DatabaseLICENSERhea has chosen to apply the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/). This means that you are free to copy, distribute, display and make commercial use of the database in all legislations, provided you credit (cite) Rhea.https://www.rhea-db.org/help/license-disclaimer
- Springer Nature
- Thieme ChemistryLICENSEThe Thieme Chemistry contribution within PubChem is provided under a CC-BY-NC-ND 4.0 license, unless otherwise stated.https://creativecommons.org/licenses/by-nc-nd/4.0/
- Wikidata
- WikipediaScopolaminehttps://en.wikipedia.org/wiki/Scopolamine
- Wiley
- Medical Subject Headings (MeSH)LICENSEWorks produced by the U.S. government are not subject to copyright protection in the United States. Any such works found on National Library of Medicine (NLM) Web sites may be freely used or reproduced without permission in the U.S.https://www.nlm.nih.gov/copyright.htmlScopolaminehttps://www.ncbi.nlm.nih.gov/mesh/68012601Adjuvants, Anesthesiahttps://www.ncbi.nlm.nih.gov/mesh/68000759Antiemeticshttps://www.ncbi.nlm.nih.gov/mesh/68000932Cholinergic Antagonistshttps://www.ncbi.nlm.nih.gov/mesh/68018680Muscarinic Antagonistshttps://www.ncbi.nlm.nih.gov/mesh/68018727
- PubChem
- GHS Classification (UNECE)GHS Classification Treehttp://www.unece.org/trans/danger/publi/ghs/ghs_welcome_e.html
- MolGenieMolGenie Organic Chemistry Ontologyhttps://github.com/MolGenie/ontology/
- PATENTSCOPE (WIPO)SID 403383516https://pubchem.ncbi.nlm.nih.gov/substance/403383516
- NCBI